Hospital
Northern Maine Medical Center
Northern Maine Medical Center was paid $5.83M by Medicaid between Jan 2018 and Nov 2024, across 191 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoNORTHERN MAINE MEDICAL CENTER
FORT KENT, ME 04743
FORT KENT, ME 04743
33aNPI1568465144assigned 05/27/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.83M
24GClaims331,094
24DCodes billed191
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maine
Rank by total paid#13 of 33
Median peer was paid$4.34M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,909 | $577K | |
| 2019 | 44,513 | $735K | |
| 2020 | 44,341 | $726K | |
| 2021 | 47,734 | $761K | |
| 2022 | 61,040 | $983K | |
| 2023 | 51,413 | $1.01M | |
| 2024incomplete | 42,144 | $1.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 12,659 | 11,518 | $1.24M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 7,355 | 6,551 | $785K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 3,807 | 3,386 | $578K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.5% | 12,338 | 10,039 | $435K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 5.6% | 8,350 | 2,321 | $325K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.7% | 2,746 | 2,323 | $214K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 2,378 | 2,119 | $177K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 2,905 | 1,611 | $176K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.3% | 906 | 849 | $133K |
| 71046 | Radiologic examination, chest; 2 views | 2.1% | 6,695 | 5,910 | $124K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 1,541 | 1,422 | $103K |
| 90792 | Psychiatric diagnostic evaluation with medical services | 1.7% | 1,481 | 1,356 | $100K |
179 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 2,880 | $75K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 2,654 | $75K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,266 | $55K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 750 | $53K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,412 | $48K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,633 | $46K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,134 | $44K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,104 | $42K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,275 | $39K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,802 | $38K |
| 20610 | <1% | 831 | $36K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 599 | $36K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,006 | $35K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 601 | $33K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 197 | $33K |
| 80061 | Lipid panel | <1% | 7,909 | $33K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,084 | $32K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,911 | $31K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,444 | $30K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,140 | $29K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,161 | $28K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 136 | $28K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,363 | $25K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,221 | $25K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 253 | $24K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 349 | $24K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,131 | $24K |
| 36415 | Collection of venous blood by venipuncture | <1% | 35,017 | $22K |
| 80053 | Comprehensive metabolic panel | <1% | 7,263 | $20K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 530 | $19K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,876 | $19K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 479 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,575 | $16K |
| 80076 | <1% | 10,936 | $16K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 277 | $16K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 611 | $13K |
| 94060 | <1% | 238 | $13K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 289 | $12K |
| 83721 | <1% | 4,074 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,120 | $11K |
| 82607 | <1% | 2,318 | $10K | |
| 73030 | <1% | 901 | $10K | |
| 82728 | <1% | 2,258 | $9K | |
| 71250 | <1% | 309 | $8K | |
| 83550 | <1% | 2,831 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 716 | $7K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 114 | $7K |
| 84439 | <1% | 2,110 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 171 | $6K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 78 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 178 | $5K |
| 86140 | <1% | 5,826 | $5K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 384 | $5K |
| 99000 | <1% | 1,569 | $5K | |
| 72100 | <1% | 206 | $5K | |
| 82746 | <1% | 981 | $5K | |
| 87088 | <1% | 2,840 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 96 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 865 | $4K |
| 83540 | <1% | 2,120 | $4K | |
| 80306 | <1% | 1,703 | $4K | |
| 83735 | <1% | 4,363 | $4K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 49 | $4K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 179 | $3K |
| 84460 | <1% | 2,238 | $3K | |
| 84450 | <1% | 2,251 | $3K | |
| 83880 | <1% | 1,182 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,213 | $3K |
| 87631 | <1% | 118 | $3K | |
| 85651 | <1% | 2,316 | $3K | |
| 85610 | <1% | 3,414 | $3K | |
| 73562 | <1% | 258 | $3K | |
| 87186 | <1% | 1,431 | $2K | |
| 93017 | <1% | 53 | $2K | |
| 81001 | <1% | 5,619 | $2K | |
| 82043 | <1% | 2,044 | $2K | |
| 87070 | <1% | 416 | $2K | |
| 87077 | <1% | 1,680 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 529 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 495 | $2K |
| 73630 | <1% | 228 | $2K | |
| 81025 | <1% | 1,367 | $2K | |
| 93226 | <1% | 75 | $2K | |
| 73502 | <1% | 197 | $2K | |
| 73610 | <1% | 174 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 119 | $2K |
| 82570 | <1% | 1,256 | $2K | |
| 83690 | <1% | 2,778 | $1K | |
| 84153 | <1% | 261 | $1K | |
| 85027 | <1% | 598 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 493 | $1K |
| 86900 | <1% | 31 | $1K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 72 | $1K |
| 99024 | <1% | 96 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 71 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 27 | $1K |
| 81002 | <1% | 815 | $908.56 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $698.30 |
| 87205 | <1% | 354 | $690.68 | |
| 76642 | <1% | 29 | $592.35 | |
| Q3014 | Telehealth originating site facility fee | <1% | 54 | $544.79 |
| 93971 | <1% | 14 | $519.82 | |
| 81003 | <1% | 1,464 | $399.46 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 56 | $394.97 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 26 | $316.08 |
| 83615 | <1% | 240 | $294.89 | |
| 73564 | <1% | 13 | $291.69 | |
| 85379 | <1% | 369 | $285.73 | |
| 94726 | <1% | 81 | $271.16 | |
| 83655 | <1% | 21 | $259.77 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 220 | $244.81 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 661 | $241.34 |
| 72070 | <1% | 15 | $201.78 | |
| 94729 | <1% | 100 | $199.48 | |
| 84100 | <1% | 147 | $165.18 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $161.16 |
| 82565 | <1% | 165 | $157.61 | |
| 82550 | <1% | 523 | $152.73 | |
| 86803 | <1% | 29 | $132.35 | |
| 99441 | <1% | 12 | $130.79 | |
| 87075 | <1% | 15 | $119.71 | |
| 82274 | <1% | 41 | $102.25 | |
| 87081 | <1% | 54 | $100.81 | |
| 93227 | <1% | 14 | $95.30 | |
| 93225 | <1% | 28 | $93.48 | |
| 84484 | <1% | 2,339 | $81.22 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 24 | $78.65 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,378 | $69.73 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 157 | $64.39 |
| 87040 | <1% | 390 | $61.92 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 175 | $60.92 |
| 87390 | <1% | 14 | $52.00 | |
| 73130 | <1% | 14 | $46.23 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,060 | $44.76 |
| 86702 | <1% | 14 | $43.16 | |
| 86701 | <1% | 14 | $35.92 | |
| 83605 | <1% | 673 | $35.26 | |
| A4206 | Syringe with needle, sterile, 1 cc or less, each | <1% | 412 | $28.83 |
| 82150 | <1% | 16 | $25.48 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,142 | $24.32 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,327 | $22.72 |
| 87340 | <1% | 13 | $20.89 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,886 | $18.60 |
| 82948 | <1% | 409 | $17.68 | |
| 85018 | <1% | 14 | $14.52 | |
| 84550 | <1% | 39 | $13.33 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $11.89 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 679 | $8.93 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,739 | $8.11 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 135 | $6.79 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 21 | $6.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 504 | $4.41 |
| 81015 | <1% | 17 | $3.47 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 14 | $2.21 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 2,203 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 343 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 16 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,771 | $0.00 |
| 88312 | 0% | 43 | $0.00 | |
| 94727 | 0% | 31 | $0.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 32 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 65 | $0.00 |
| 84520 | 0% | 12 | $0.00 | |
| 90715 | 0% | 12 | $0.00 | |
| 82553 | 0% | 297 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 776 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,047 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 671 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 174 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 980 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 99 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 78 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 101 | $0.00 |
| 80320 | 0% | 32 | $0.00 | |
| 86901 | 0% | 31 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 34 | $0.00 |
| 36416 | 0% | 21 | $0.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 30 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZEWE, JEFFREY (CEO)
| Provider | Location | Paid |
|---|---|---|
| Northern Maine Medical Center | Fort Kent, ME | $3.00M |
| Northern Maine Medical Center | Madawaska, ME | $2.80M |
| Northern Maine Medical Center | Fort Kent, ME | $1.53M |
| Northern Maine Medical Center | Fort Kent, ME | $1.32M |
| Northern Maine Medical Center | Madawaska, ME | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.